While the PRISM III score did not show a significant difference between survivors and non-survivors, NGAL demonstrated higher sensitivity in predicting outcomes, suggesting its potential role in early diagnosis and intervention for sepsis-related mortality in pediatric patients. This evidence concerns the gene LCN2 and Sepsis.